Biote Corp. (BTMD) Earnings Call Analysis

NASDAQ · Healthcare · Medical Care Facilities

6/25

Growth 1 Margin 1 Expansion 2 Platform 1 Financial 1

latest quarter score

Earnings Reports

6
BTMD Q2 2026: Revenue Guidance Cut by $15M as Recall Fallout Delays Recovery
August 06, 2026
19
Biote (BTMD) Q1 2026: Recall Drives $1.7M Revenue Hit, Sales Force Expansion Sets Up H2 Rebound
May 07, 2026
13
BioT (BTMD) Q4 2025: Sales Force Expands 33% as Clinic Attrition Stabilizes, Setting Stage for H2 Recovery
March 12, 2026
13
BioTE (BTMD) Q3 2025: Procedure Revenue Down 10.4% as Sales Force Transition Delays Growth Rebound
November 06, 2025
14
Biote Corp. (BTMD) Q2 2025: Procedure Revenue Declines 8.4% Amid Strategic Reorganization
August 06, 2025
10
BIOTE (BTMD) Q1 2025: Dietary Supplement Revenue Jumps 26% as Sales Force Realignment Targets Clinic Growth
July 04, 2025
19
Biote Corp. (BTMD) Q4 2024: 9% Revenue Growth Amid Software Transition Challenges
March 12, 2025
BioT (BTMD) Q3 2024: Software Rollout Triggers 2.5 Point Headwind, Margin Expansion Holds
November 12, 2024
BioT (BTMD) Q2 2024: Procedure Revenue Climbs 7.8% as BioTRx Platform Expansion Accelerates Clinic Growth
August 08, 2024
BTMD Q1 2024: 6.6% Procedure Growth Anchored in Existing Clinics as Internal Production Ramps
May 07, 2024
BioT (BTMD) Q4 2023: BioTRx Launch and 403bp Margin Expansion Signal Competitive Reset
March 12, 2024

Browse all companies